Related references
Note: Only part of the references are listed.Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms
T. Al-Toubah et al.
ESMO OPEN (2022)
Final overall survival results from the NICE-NEC trial (GETNE-T1913): A phase II study of nivolumab and platinum-doublet chemotherapy (CT) in untreated advanced G3 neuroendocrine neoplasms (NENs) of gastroenteropancreatic (GEP) or unknown (UK) origin
M. C. Riesco Martinez et al.
ANNALS OF ONCOLOGY (2022)
Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System The TOPIC-NEC Phase 3 Randomized Clinical Trial
Chigusa Morizane et al.
JAMA ONCOLOGY (2022)
Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System The TOPIC-NEC Phase 3 Randomized Clinical Trial
Chigusa Morizane et al.
JAMA ONCOLOGY (2022)
Nivolumab (nivo) ± ipilimumab (ipi) in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) (GCO-001 NIPINEC)
N. Girard et al.
ANNALS OF ONCOLOGY (2021)
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study
Jonathan Strosberg et al.
CLINICAL CANCER RESEARCH (2020)
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors
Sandip P. Patel et al.
CLINICAL CANCER RESEARCH (2020)
Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials
Namrata Vijayvergia et al.
BRITISH JOURNAL OF CANCER (2020)
Etoposide and cisplatin versus irinotecan and cisplatin as the first-line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: A randomized phase 2 study
Panpan Zhang et al.
CANCER (2020)
Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers
Oliver Klein et al.
CLINICAL CANCER RESEARCH (2020)
Phase II study of pembrolizumab-based therapy in previously treated extrapulmonary poorly differentiated neuroendocrine carcinomas: Results of Part A (pembrolizumab alone).
Claire Mulvey et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Luis Paz-Ares et al.
LANCET (2019)
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
L. Horn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Comparative Study of Lung and Extrapulmonary Poorly Differentiated Neuroendocrine Carcinomas: A SEER Database Analysis of 162,983 Cases
Arvind Dasari et al.
CANCER (2018)
Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study
H. Sorbye et al.
ANNALS OF ONCOLOGY (2013)
Cisplatin and Etoposide as First-line Chemotherapy for Poorly Differentiated Neuroendocrine Carcinoma of the Hepatobiliary Tract and Pancreas
Satoru Iwasa et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2010)
Share Paper
